Clinuvel Pharmaceuticals (ASX:CUV) expanded its Vallaurix research, development, and innovation center in Singapore with a five-year investment, supported by the Singaporean Economic Development Board, according to a Monday filing with the Australian bourse.
The investment will ensure that ongoing projects in novel pharmaceutical and PhotoCosmetic formulation continue uninterrupted, the filing said.
The company's shares added 2% in recent Monday trade.